Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Autolus Therapeutics plc is a biopharmaceutical company specializing in next-generation programmed T cell therapies for cancer and autoimmune diseases. Its core product, AUCATZYL (obe-cel), is an autologous CD19-targeting CAR T cell therapy approved for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Autolus develops modular, engineered T cell therapies designed to improve efficacy, safety, and durability, supported by proprietary manufacturing and global commercial capabilities targeting hematological and solid tumor markets.
This description was generated via AI from an annual report. Updated about 1 year ago.